NCT03410043View on ClinicalTrials.gov

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
DRUG

Osimertinib

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

M D Anderson Cancer Center, Houston

94115

UCSF Medical Center-Mount Zion, San Francisco

80217-3364

University of Colorado, Denver

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Comprehensive Cancer Network

NETWORK

lead

M.D. Anderson Cancer Center

OTHER